Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.

Saved in:
Bibliographic Details
Title: Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Authors: Craig TJ; Allergy, Asthma and Immunology, Department of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Vinmec International Hospital, Hanoi, Vietnam. Electronic address: tcraig@pennstatehealth.psu.edu., Levy DS; Division of Allergy and Immunology, University of California, Irvine, CA, USA., Reshef A; Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel., Lumry WR; AARA Research Center, Dallas, TX, USA., Martinez-Saguer I; HZRM Haemophilia Center Rhein Main, Mörfelden-Walldorf, Germany., Jacobs JS; Allergy & Asthma Clinical Research, Walnut Creek, CA, USA., Yang WH; Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, ON, Canada., Ritchie B; Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada., Aygören-Pürsün E; Department of Pediatrics, University Hospital, Goethe University Frankfurt, Frankfurt, Germany., Keith PK; McMaster University Medical Centre Site, Hamilton, ON, Canada., Busse P; Mount Sinai, New York, NY, USA., Feuersenger H; CSL Behring Innovation GmbH, Marburg, Germany., Alexandru Bica M; CSL Behring Innovation GmbH, Marburg, Germany., Jacobs I; CSL Behring, King of Prussia, PA, USA., Pragst I; CSL Behring Innovation GmbH, Marburg, Germany., Magerl M; Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Freie Universität Berlin, Berlin, Germany; Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
Source: The Lancet. Haematology [Lancet Haematol] 2024 Jun; Vol. 11 (6), pp. e436-e447. Date of Electronic Publication: 2024 May 03.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3026
DOI:10.1016/S2352-3026(24)00081-4